Quanterix was formed in 2007 with a focus on building a “single molecule” detection platform with a focus on proteomics applications. They raised a total of $533.33M and exited via IPO in 2017. They position themselves as being very high sensitivity, for diagnostics applications. So (as they suggest) you have pretty much every other current and next-gen proteometics player working on “Research Proteomics”, then Quanterix coming in with high sensitivity on the Simoa platform which would be applied to diagnostics:

Read →